Profile data is unavailable for this security.
About the company
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.
- Revenue in USD (TTM)119.00k
- Net income in USD-65.88m
- Incorporated2010
- Employees102.00
- LocationFractyl Health Inc3 Van De Graaff Drive, Suite 200BURLINGTON 01803United StatesUSA
- Phone+1 (781) 902-8800
- Fax+1 (302) 655-5049
- Websitehttps://www.fractyl.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agenus Inc | 159.63m | -223.67m | 114.33m | 389.00 | -- | -- | -- | 0.7162 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| INmune Bio Inc | 85.00k | -37.74m | 114.41m | 11.00 | -- | 2.74 | -- | 1,346.00 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 115.61m | 25.00 | -- | 3.74 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 116.43m | 140.00 | -- | 38.91 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -137.29m | 117.83m | 143.00 | -- | 0.5012 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 118.98m | 93.00 | 8.24 | 1.26 | 6.59 | 211.33 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 119.82m | 246.00 | -- | -- | -- | 0.3889 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 120.10m | 31.00 | -- | 2.25 | -- | 180.60 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Nuvectis Pharma Inc | 0.00 | -21.10m | 120.31m | 13.00 | -- | 9.65 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 121.74m | 102.00 | -- | 1.72 | -- | 1,022.98 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 122.52m | 112.00 | -- | -- | -- | 4.95 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -83.84m | 123.30m | 64.00 | -- | 1.37 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Puma Biotechnology Inc | 219.14m | 8.72m | 125.07m | 185.00 | 13.93 | 2.55 | 6.16 | 0.5707 | 0.183 | 0.183 | 4.56 | 1.00 | 1.08 | 7.07 | 7.38 | 1,184,557.00 | 4.30 | -12.21 | 7.24 | -20.53 | 73.08 | 78.78 | 3.98 | -11.79 | 1.23 | 1.99 | 0.6474 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Actuate Therapeutics Inc | 0.00 | -27.77m | 127.28m | 6.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | -0.7114 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -134.25 | -- | -- | -- | -- | -22.74 | -- | -- | -- |
| CervoMed Inc | 9.65m | -5.04m | 128.76m | 8.00 | -- | 2.58 | -- | 13.34 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Quantum-Si Inc | 1.70m | -89.35m | 129.55m | 159.00 | -- | 0.5552 | -- | 76.12 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to Fractyl Health Inc's reporting currency: US Dollar USD
26.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Maverick Capital Ltd.as of 31 Mar 2024 | 4.25m | 8.88% |
| M28 Capital Management LPas of 31 Mar 2024 | 1.86m | 3.88% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.70m | 3.55% |
| Corebridge Institutional Investments (US) LLCas of 31 Mar 2024 | 1.34m | 2.80% |
| Massachusetts Financial Services Co.as of 30 Jun 2024 | 996.38k | 2.08% |
| Ensign Peak Advisors, Inc.as of 31 Mar 2024 | 834.25k | 1.74% |
| 683 Capital Management LLCas of 31 Mar 2024 | 750.00k | 1.57% |
| Millennium Management LLCas of 31 Mar 2024 | 382.31k | 0.80% |
| Balyasny Asset Management LPas of 31 Mar 2024 | 314.06k | 0.66% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 271.81k | 0.57% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
